Knight Therapeutics Inc. (TSX:GUD)
Canada · Delayed Price · Currency is CAD 11.70
0.00 (0.00%)
Oct 22, 2026, 4:00 PM EDT
Knight Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Knight Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $11.65. The average 1-year stock price forecast is 0.43% lower than the current stock price, while the lowest is $10.80 (-7.69%) and the highest is $14.00 (+19.66%).
Price Target: $11.65 (-0.43%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Knight Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | May '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $11.00 → $12.25 | Buy | Maintains | $11.00 → $12.25 | +4.70% | Oct 16, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $9.50 → $11.00 | Buy | Maintains | $9.50 → $11.00 | -5.98% | Aug 7, 2026 |
| Bloom Burton | Bloom Burton | Buy Maintains $12.00 | Buy | Maintains | $12.00 | +2.56% | Aug 7, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Initiates $9.50 | Buy | Initiates | $9.50 | -18.80% | May 8, 2026 |
Financial Forecast
Revenue This Year
552.44M
from 450.09M
Increased by 22.74%
Revenue Next Year
552.84M
from 552.44M
Increased by 0.07%
EPS This Year
0.14
from 0.02
Increased by 500.86%
EPS Next Year
0.26
from 0.14
Increased by 85.71%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CAD.